HPLC method development and validation of candesartan cilexetil for pharmacokinetics parameter assessment

Abstract

In this study, healthy volunteers in Pakistan were asked to compare the single-dose pharmacokinetics of 16 mg of the angiotensin receptor blocker candesartan cilexetil following oral administration. Blood samples were taken over a 72-hour period while the medication was administered orally to 16 healthy individuals. Following a freeze-thaw cycle, the samples were subjected to reversed-phase HPLC analysis at a wavelength of 258 nm using an isocratic mobile phase consisting of potassium dihydrogen phosphate and methanol (25:75 v/v). Pharmacokinetic parameters such as Cmax, Tmax, t1/2, Ka, Vd, and AUC were computed.